linjc16/ctgov huggingface dataset:
Deep Learning to Summarize Findings in Dental Panoramic Radiographs

Study Overview
=================
Brief Summary
-----------------
In this work, the investigators study the application of artificial intelligence systems on dental panoramic images for dental findings. An artificial intelligence system will be learned on an publicly available panoramic image dataset, and test against the investigators' local patient cohort as external test data. The investigators hypothesize the performance would be similar, if not identical to on the public data, and that the investigators' AI system is generalizable.

Official Title
-----------------
Deep Learning to Summarize Findings in Dental Panoramic Radiographs

Conditions
-----------------
Radiography, Digital, Dental Diseases, Dentist-Patient Relations

Intervention / Treatment
-----------------
* Radiation: Dental Panoramic Radiographs


Participation Criteria
=================
Eligibility Criteria
-----------------
Exclusion Criteria: patients under 20 or with primary teeth patients with non-removable metal accessory above neck, such as tongue ring, nose ring etc. patients with mandible or maxilla deformation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All patients with relevant dental findings<br> | Radiation: Dental Panoramic Radiographs<br>* Exposure to dental panoramic radiographs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Area Under Curve for Receiver Operating Characteristics of Clinical Findings | The investigators use the AI model to infer whether a clinical finding (out of the six type of findings the investigators are interested in) is present in an imaging study from the test set. The result is compared against expert annotation and evaluated for receiver operating characteristics over the whole set. The area under curve will then be calculated and averaged across six type of findings to represent the overall efficacy of the model on detecting findings from panoramic images. From a scale of zero to one, zero is the worst this metric can be and one is the best. | 1 day |
Long Term Follow up After 1 Year Initial Lifestyle Intervention

Study Overview
=================
Brief Summary
-----------------
The effect of non-surgical methods for obesity treatment are not fully documented. This study focus on the long term effect of an intensiv follow up (the Evje Model) compared to a regular follow up. The Evje Model is a combined model, consisting of repeated stays at a specialist centre, telephone follow up at home, home groups, self monitoring and close contact with the patients' local physician.

Detailed Description
-----------------
Eighty patients will undergo an intensive lifestyle intervention following the Evje Model. This group will be randomised into an intervention group and a control group. The intervention group will undergo four years of further follow up in accordance with the Evje Model, which means two one weeks stays each year at the Evje Clinic, telephone follow up, home groups, self monitoring and collaboration with the patients' local physician. The control group will be followed up by the patients local physician and a yearly control at the Center for Morbid Obesity at Vestfold Hospital (Sykehuset i Vestfold HF). The control group will have a yearly week end at Evjeklinikken for testing. The purpose is to measure the effect of these two follow up models in regard to weight loss maintanance, Quality of Life and comorbidities.

Official Title
-----------------
Effect of Four Years Intensive- Versus Regular Follow up, After a One Year Weight Loss Period, in Patients With Morbid Obesity.

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: The Evje Model


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients, referred from Public Hospitals, with morbid obesity that have undergone one year intensive life style intervention in accordance with the Evje Model. Exclusion Criteria: Pregnancy, major and active psychiatric disease, active and serious eating disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 67 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: The Evje Model|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obesity, Weight loss maintenance, QOL, Life Style, Follow Up
Periodontal Profile of Hypogonadic Men

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess if hypogonadic men with periodontitis benefit from testosterone replacement therapy before being submitted to periodontal treatment. Fifty hypogonadic men (Total Testosterone <200ng/dL) will be recruited from the Clinics Hospital at Federal University of Paraná and subjected to periodontal evaluation by a trained and calibrated researcher. The subjects presenting with periodontitis (assessed by clinical parameters) will be randomly allocated to testosterone replacement therapy (TRT) group or placebo for 3 months. After that time, all patients will receive nonsurgical periodontal treatment, which will be reassessed after 45 days. Clinical parameters (such as probing depth, gingival and plaque index, clinical attachment loss, bleeding on probing), sub gingival plaque and gingival crevicular fluid will be collected at baseline, just before therapy and 45 days after therapy.

Official Title
-----------------
Clinical, Microbiologic and Immunologic Profile of the Periodontal Condition in Hypogonadic Men

Conditions
-----------------
Periodontitis, Hypogonadism, Male

Intervention / Treatment
-----------------
* Drug: Testosterone gel
* Drug: Placebos


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: total testosterone <200ng/dL in two assessments; at least 20 teeth present. - Exclusion Criteria: systemic diseases such as hormonal, inflammatory and immune alterations. -

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Placebo and TRT groups
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo<br>Gel, daily | Drug: Placebos<br>* Placebo, gel, daily<br>|
| Experimental: TRT<br>Testosterone Replacement Therapy | Drug: Testosterone gel<br>* Androgel (50mg testosterone), gel, daily<br>* Other names: TRT;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CAL | Clinical Attachment Loss | 4.5 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PPD | probing pocket depth | 4.5months | 
| PPD | probing pocket depth | 3months | 
| BOP | bleeding on probing | 3months | 
| BOP | bleeding on probing | 4.5months | 
| Micro-organisms concentration | DNA hybridization - checkerboard | 4.5months | 
| Micro-organisms concentration | DNA hybridization - checkerboard | 3months | 
| Concentration of inflammatory markers in crevicular fluid | Multiplex assay | 3months | 
| Concentration of inflammatory markers in crevicular fluid | Multiplex assay | 4.5 months |
Changes in the Consumption of Psychoactive Substances During Containment Linked to COVID-19

Study Overview
=================
Brief Summary
-----------------
The SARS-CoV 2 pandemic started in China in December 2019, then reached France on January 24, 2020. On March 14, France moved into phase 3 of the epidemic threshold with the implementation of containment measures on March 17 Measures were put in place by N.Belloubet (French Minister of Justice) from March 17, including suspension of visiting rooms and activities in detention. Containment provides boredom and isolation with many potential consequences: sleep disturbance, anxiety, PTSD, depression, suicide, addictive behavior and violence. However,prisoners have a higher prevalence of substance use disorders than the general population. What will have been the impact of the confinement on the consumption of psychoactive substances by prisoners at the Villeneuve Les Maguelone prison. Anonymous questionnaire from the start Collection of socio-demographic data Collection of consumption data before and during containment Collection of monitoring data

Official Title
-----------------
Changes in the Consumption of Psychoactive Substances by People Incarcerated at the Villeneuve-Lès-Maguelone Prison During Containment Linked to COVID-19.

Conditions
-----------------
People Incarcerated, COVID-19

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Men incarcerated at Villeneuve Les Maguelone prison On a given date (May 12) Major French speaking non illiterate Exclusion criteria: minors patients refusing non-French speaking illiterate

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percentage changes in the consumption of psychoactive substances | percentage changes in the consumption of psychoactive substances | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of the level of stress | Assessment of the level of stress by self-administered questionnaire before / during confinement | 1 day | 
| Assessment of depression | Assessment of depression by self-administered questionnaire before / during confinement | 1 day | 
| Craving modification evaluation | Craving modification evaluation | 1 day |
The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST)

Study Overview
=================
Brief Summary
-----------------
This study is to collect the information of Ultravist® in the patients indicated for the coronary angiography or PCI, like rate of ADR in patients, the dose for different indications, image quality to prove Ultravist the good safety and effectivity

Official Title
-----------------
This is an International, Prospective, Non-interventional Study, Company Sponsored, Multi-center Study. Patients Undergo Coronary Angiography or PCI Procedure With Ultravist. The Primary Objective is to Evaluate the Safety and Tolerability.

Conditions
-----------------
Angiocardiography

Intervention / Treatment
-----------------
* Drug: Iopromide (Ultravist, BAY86-4877)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female and male patients who receive Ultravist® for coronary angiography or PCI can be included in the study Exclusion Criteria: Patients who are or are suspected in pregnancy or nursery Patients with the contraindications for Ultravist Patients with the contraindications for cardiac catheterization
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br> | Drug: Iopromide (Ultravist, BAY86-4877)<br>* Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the safety and tolerability of Ultravist® in patients Undergoing cardiac catheterization. |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimation of the image quality of Ultravist® |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Survey, Angiography, ADR, Image quality
Efficacy and Safety Oral Contraceptive Study

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the study drug is effective in prevention of pregnancy in healthy women in reproductive age

Detailed Description
-----------------
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Official Title
-----------------
Multi-center, Open, Uncontrolled Study to Investigate the Efficacy and Safety of the Oral Contraceptive SH T 186 D Containing 0.02 mg Ethinylestradiol-b-cyclodextrin Clathrate and 3 mg Drospirenone in a 24-day Regimen for 13 Cycles in 1010 Healthy Female Volunteers

Conditions
-----------------
Contraception

Intervention / Treatment
-----------------
* Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy woman requesting contraception Age between 18 and 35 years (inclusive), smokers maximum age of 30 years (inclusive) Exclusion Criteria: Any conditions might interfere study outcome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br> | Drug: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)<br>* Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of unintended pregnancies (Pearl index) |  | 13 cycles of 28 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physical and gynecological examination |  | screening, cycle 6 and final examination | 
| Vital signs |  | each visit | 
| Body weight |  | each visit | 
| Cervical smear |  | each visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Oral contraception
T Regulatory and Childhood Asthma

Study Overview
=================
Brief Summary
-----------------
This is an epidemiologic study, examining environmental exposures and affect on immune development.

Detailed Description
-----------------
This is an epidemiologic study, examining environmental exposures and affect on immune development. The study has completed enrollment

Official Title
-----------------
T Regulatory and Childhood Asthma

Conditions
-----------------
Childhood Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: moderate to severe asthma Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 7 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1.<br>Children with asthma | |
| 2.<br>Children without asthma | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Childhood asthma |  | 3 years | 
| Allergic sensitization |  | 3 years |
MK0653A (Ezetimibe (+) Simvastatin) Compared to an Approved Drug (Atorvastatin) for the Treatment of High Cholesterol (0653A-051)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
This study is to assess the safety and efficacy of an investigational drug as compared to an approved drug to reduce specific cholesterol levels.

Detailed Description
-----------------
The duration of treatment is 6 weeks.

Official Title
-----------------
A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia

Conditions
-----------------
Hypercholesterolemia

Intervention / Treatment
-----------------
* Drug: MK0653A, ezetimibe (+) simvastatin
* Drug: Comparator: atorvastatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elevated cholesterol Exclusion Criteria: Unstable medical conditions or significant heart problems within 3 months prior to first study visit.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 79 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: MK0653A, ezetimibe (+) simvastatin|nan|
|Drug: Comparator: atorvastatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma LDL-C averaged across all doses after 6 weeks |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma LDL-C for each dose; plasma HDL-C averaged across all doses |  |  |
Efficacy of Warming Device During Surgery

Study Overview
=================
Brief Summary
-----------------
This study will test the hypothesis that an electric heating device, the Hot Dog warming system is as effective as the Bair Hugger forced air heating system.

Detailed Description
-----------------
Subjects undergoing major plastic surgery lasting approximately 5 hours will be randomized to either the Hot Dog resistive heating system or the Bair Hugger forced air heating system. Core temperature will be measured using a distal esophagus and mean skin temperature. Warming will continue until the subjects' core temperature reaches 37°C. Subsequent temperature will be adjusted as clinically necessary. Data will be recorded at 15 minute intervals. Core temperature will be first measured after intubation when the esophageal temperature probe is inserted. The primary outcome will be the rate of core rewarming over the range of 35°C to 37°C.

Official Title
-----------------
Efficacy of a New Intraoperative Resistive Warming Device

Conditions
-----------------
Surgery

Intervention / Treatment
-----------------
* Device: Intraoperative warming with Bair Hugger forced air system
* Device: Intraoperative warming with Hotdog resistive heating system


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Plastic surgery lasting approximately 5 hours Subjects over the age of 18 years Patient signed Informed Consent Exclusion Criteria: Plastic surgery lasting less than 5 hours Individuals under the age of 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1: Bair Hugger<br>Intraoperative warming with Bair Hugger forced air system | Device: Intraoperative warming with Bair Hugger forced air system<br>* Intraoperative warming with Bair Hugger forced air system<br>|
| 2: Hot Dog<br>Intraoperative warming with Hot Dog resistive heating system | Device: Intraoperative warming with Hotdog resistive heating system<br>* Intraoperative warming with Hotdog resistive heating system<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Rate of Core Rewarming Over the Range From 35°C to 37°C. | The primary outcome was the rewarming rate during active heating over a core temperature range from 35°C to 37°C. | Until the end of surgery, up to 5 hour | 
| Intraoperative Time Weighted Average Core Temperature | Temperatures during surgery were recorded at 15-min intervals and summarize as time weighted average (TWA) for each patient. The unit of TWA-temperature is °C. | Until the end of surgery, up to 5 hour | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bair Hugger, Plastic surgery, Warming, Core temperature, Hot Dog heating system